biotech / news / / Devdiscourse
Novo Nordisk shares rose 5.8% by 0913 GMT, marking the highest daily increase this year.
Novo Nordisk's Wegovy pill generated 2.26 billion crowns in sales, nearly double analyst expectations.
KEY POINTS
- Novo now expects 2024 sales and profit to decline by 4–12%, a modest improvement over previous guidance.
- Wegovy pill prescriptions surpassed 2 million since January, marking the largest GLP-1 launch in U.S. history.
- Over half of U.S. Wegovy sales are now self-pay, up from 10% a year earlier.
- Lilly's Foundayo FDA approval in April ended Wegovy's status as the only U.S. oral obesity pill.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →